Use of pentoxifylline in membranous nephropathy

被引：58

作者：

Ducloux, D ^{[1
]}

Bresson-Vautrin, C ^{[1
]}

Chalopin, JM ^{[1
]}

机构：

[1] Hop St Jacques, Dept Nephrol Dialysis & Renal Transplantat, F-25030 Besancon, France

来源：

LANCET | 2001年 / 357卷 / 9269期

关键词：

D O I：

10.1016/S0140-6736(00)04830-3

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Urinary TNF-alpha excretion correlates with proteinutia in patients with membranous nephropathy (MGN). Pentoxifylline suppresses or reduces the production of TNF-alpha. Between April, 1999 and August, 2000, we did a single-centre, prospective, pilot study to assess the effects of pentoxifylline (1200 mg/day) on proteinuria in patients with idiopathic MGN. Ten patients were included and treated fore months. Pentoxifylline significantly decreased proteinuria from 11 g/day [range 4.6-27] to 1.8 (0-10.9); p=0.001). Pentoxifylline may be a safe and effective adjunct to steroids and immunosuppressants in patients with MGN.

引用

页码：1672 / 1673

页数：2